These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16750544)

  • 1. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.
    Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F
    Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
    Cippitelli A; Bilbao A; Hansson AC; del Arco I; Sommer W; Heilig M; Massi M; Bermúdez-Silva FJ; Navarro M; Ciccocioppo R; de Fonseca FR;
    Eur J Neurosci; 2005 Apr; 21(8):2243-51. PubMed ID: 15869521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats.
    Rutkowska M
    Acta Pol Pharm; 2004; 61(5):401-3. PubMed ID: 15747698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A.
    De Vry J; Schreiber R; Eckel G; Jentzsch KR
    Eur J Pharmacol; 2004 Jan; 483(1):55-63. PubMed ID: 14709326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
    Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.
    Ward SJ; Lefever TW; Rawls SM; Whiteside GT; Walker EA
    Psychopharmacology (Berl); 2009 Sep; 206(1):155-65. PubMed ID: 19575185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
    Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P
    Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.
    Alonso M; Serrano A; Vida M; Crespillo A; Hernandez-Folgado L; Jagerovic N; Goya P; Reyes-Cabello C; Perez-Valero V; Decara J; Macías-González M; Bermúdez-Silva FJ; Suárez J; Rodríguez de Fonseca F; Pavón FJ
    Br J Pharmacol; 2012 Apr; 165(7):2274-91. PubMed ID: 21951309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
    Tallett AJ; Blundell JE; Rodgers JR
    Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats.
    Navarro M; Carrera MR; Del Arco I; Trigo JM; Koob GF; Rodríguez de Fonseca F
    Eur J Pharmacol; 2004 Oct; 501(1-3):235-7. PubMed ID: 15464083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.
    Vickers SP; Webster LJ; Wyatt A; Dourish CT; Kennett GA
    Psychopharmacology (Berl); 2003 Apr; 167(1):103-11. PubMed ID: 12632249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats.
    Tallett AJ; Blundell JE; Rodgers RJ
    Pharmacol Biochem Behav; 2009 Jan; 91(3):358-66. PubMed ID: 18755211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals.
    Lallemand F; Soubrié P; De Witte P
    Alcohol Alcohol; 2004; 39(6):486-92. PubMed ID: 15466898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.